Is Express Scripts Setting A Dangerous Precedent?

January 6, 2015 12:13 PM

4 0

One of the most talked about biotechnology stocks in 2014 was Gilead Sciences (NASDAQ:GILD). The reason of course was Gilead's hepatitis C treatments, Sovaldi and Harvoni. Sovaldi, which was approved last year, became a blockbuster drug in no time. Harvoni is on its way.

The success of Sovaldi and Harvoni propelled Gilead shares to new highs. Up until two weeks ago, the stock was headed for a gain of more than 45% for 2014. A commendable performance in what was a challenging year for the biotechnology sector in general. However, Gilead shed some of its gains in the ...

Also read: BAT heaps $47 bln of peer pressure on Reynolds

Read more

To category page